利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

64 条记录 (耗时 0.032 秒)

    Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
    1.
    发明授权
    Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof 有权

    公开(公告)号：US11942149B2

    公开(公告)日：2024-03-26

    申请号：US17883158

    申请日：2022-08-08

    申请人： MacroGenics, Inc.

    发明人： Liqin Liu ,  Chia-Ying Kao Lam ,  Gundo Diedrich ,  Leslie S. Johnson ,  Paul A. Moore ,  Ezio Bonvini

    IPC分类号： G11C13/00 ,  G11C15/00

    CPC分类号： G11C13/0026 ,  G11C13/004 ,  G11C15/00 ,  G11C2013/0045

    摘要： The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA. The CD137×TA Binding Molecules of the invention are capable of simultaneous binding to CD137, and a TA. The invention is directed to pharmaceutical compositions that contain any such CD137×TA Binding Molecules. The invention is additionally directed to methods for the use of such molecules in the treatment of cancer and other diseases and conditions. The invention also provides novel CD137-binding molecules, and HER2/neu-binding molecules, as well as derivatives thereof and uses thereof.

    Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof
    4.
    发明申请
    Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof 有权

    公开(公告)号：US20220372144A1

    公开(公告)日：2022-11-24

    申请号：US17835441

    申请日：2022-06-08

    申请人： MacroGenics, Inc.

    发明人： Leslie S. Johnson ,  Ling Huang ,  Kalpana Shah ,  Ezio Bonvini ,  Paul A. Moore ,  Wei Chen

    IPC分类号： C07K16/28 ,  C07K16/46

    摘要： The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.

    PD-1-BINDING MOLECULES AND METHODS OF USE THEREOF
    6.
    发明申请
    PD-1-BINDING MOLECULES AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：US20200231675A1

    公开(公告)日：2020-07-23

    申请号：US16752464

    申请日：2020-01-24

    申请人： MACROGENICS, INC

    发明人： Kalpana Shah ,  Douglas H. Smith ,  Ross La Motte-Mohs ,  Leslie S. Johnson ,  Paul A. Moore ,  Ezio Bonvini ,  Scott Koenig

    IPC分类号： C07K16/28

    摘要： The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.

    Covalently Bonded Diabodies Having Immunoreactivity with PD-1 and LAG-3, and Methods of Use Thereof
    7.
    发明申请
    Covalently Bonded Diabodies Having Immunoreactivity with PD-1 and LAG-3, and Methods of Use Thereof 审中-公开

    公开(公告)号：US20190169292A1

    公开(公告)日：2019-06-06

    申请号：US16189071

    申请日：2018-11-13

    申请人： MacroGenics, Inc.

    发明人： Ezio Bonvini ,  Leslie S. Johnson ,  Kalpana Shah ,  Ross La Motte-Mohs ,  Paul A. Moore ,  Scott Koenig

    IPC分类号： C07K16/28 ,  C07K16/46

    摘要： The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”). The present invention also is directed to such diabodies that additionally comprise an immunoglobulin Fc Domain (“bi-specific Fc diabodies and bi-specific, tetra-valent, Fc diabodies”). The diabodies of the present invention are capable of simultaneously binding to PD-1 and to LAG-3, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such diabodies, and to methods involving the use of such diabodies in the treatment of cancer and other diseases and conditions.

    PD-1-Binding Molecules and Methods of Use Thereof
    8.
    发明申请
    PD-1-Binding Molecules and Methods of Use Thereof 审中-公开

    公开(公告)号：US20190127467A1

    公开(公告)日：2019-05-02

    申请号：US15748458

    申请日：2016-07-28

    申请人： MacroGenics, Inc.

    发明人： Kalpana Shah ,  Douglas H. Smith ,  Ross La Motte-Mohs ,  Leslie S. Johnson ,  Paul A. Moore ,  Ezio Bonvini ,  Scott Koenig

    IPC分类号： C07K16/28

    摘要： The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.